藥 品

劑量

副作用

藥物相互作用

Insulin 胰島素 100U/mL

•低血糖反應

•Somogyi效應:低血糖反

應後之高血糖

•胰島素過敏

•胰島素抗體

•注射部位脂肪萎縮,脂肪

增生

•胰島素水腫

•肝臟腫大

•肥胖

　

　

被影響:Phenytoin,ACE inhibitor,Anabolic steroid,

Calcium channel blockers,

Clonidine,

Catecholamine,

Glucocorticoid,

Guanethidine,

Isoniazide,Aspirin,

Tetracycline,Thiazide,

Oral contraceptive,GH

影響:Guanethidine,

Debrisoquin,Colestipol

　

　

Regular insulin短效

[Humulin R-Lilly]

[Velosulin HM-Novo]

[Actrapid HM-Novo]

IV/IM/SC

　

　

　

　

Adolesecent 0.8-1.2U/Kg/D

DKA 0.1U/Kg/hr [type1]

DKA/HHNK

50U Iv push

10-20U/hr IV infusion

NPH insulin中效

[Humulin N-Lilly]

[Insulatard HM-Novo]

[Protaphane HM-Novo]

SC

　

Type 1/2 : 0.5-1U/Kg/D

Type1≒ ≦40U/D

Type2 Urine ketone[-]

0.3-0.5U/Kg/D

Urine ketone[+]

0.5-0.7U/kg/D

Ultralent insulin 長效

[Humulin L-Lilly]

[Monotard HM-Novo]

[Ultratard HM-Novo]

SC

　

Pre-mixture短效+中效

[Humulin Mixture-

80/20,70/30- Lilly]

[Mixtard 30HM=70/30-Novo]

Insulin lispro修飾型超短效

[Humalog-Lilly]IV/IM/SC

被影響:(↓Insulin lispro 之作用):

Corticosteroid,

Thyroxine,Diltiazem,

Dobutamine,

Epinephrine,Oral contraceptive,Smoking,

Thiazide diuretics

被影響:(↑Insulin lispro 之作用):Alcohol

,Anabolic steroid,

β-blockers,clofibrate,

Guanethidine,

Fenfluramine,MAO inhibitors,

Phenylbutazone,

Salicylate,Sulpyrazone,

Tetracycline